Amplification and/or overexpression of HER-2/neu are associated with poor clinical outcome in several epithelial tumours. The exact prognostic role of HER-2/neu expression in testicular germ-cell tumours is not well examined. Since teratomas are relatively chemoresistant tumors, we evaluated the HER-2/neu alterations of 59 primary testicular teratomas and mixed germ-cell tumours containing teratoma components using standardized immunohistochemical method (IHC) (HercepTest™) and Fluorescence in Situ Hybridization (FISH). HER-2/neu overexpression was detected in 14 (24%) of 59 specimens. With IHC, teratoma and choriocarcinoma components showed significantly higher HER-2/neu expression compared to other histological subtypes of GCTs (p=0.0095). A statistically significant correlation (p=0.0004) can be established between HER-2/neu status and clinical stage of the disease. Similarly, a significant correlation was observed between HER-2/neu overexpression and clinical outcome (p=0.0077). None of the specimens had definite HER-2/neu gene amplification. Our results suggest that HER-2/neu overexpression is associated with an adverse clinical outcome and has a prognostic role in testicular germ-cell tumours.
|Translated title of the contribution||Clinical relevance of HER-2/neu expression in germ-cell testicular tumors|
|Number of pages||8|
|Publication status||Published - dec. 1 2004|
- Germ-cell testicular tumour
ASJC Scopus subject areas